Drugs / CS-3150
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04019652 | Nov → Dec 2015 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02448628 | May → Dec 2015 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT02345044 | Jan → Aug 2015 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT02345057 | Jan 2015 → Jun 2016 | diabetic kidney disease | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT02890173 | Sep 2016 → Jul 2017 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT02807974 | Jun 2016 → Mar 2017 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT02807987 | Jun 2016 → May 2017 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT02808026 | Jun 2016 → Feb 2017 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT02722265 | Mar 2016 → Jul 2017 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02885662 | Sep 2016 → Jul 2017 | primary aldosteronism | Daiichi Sankyo | Completed | No outcome recorded |
| — | NCT02848170 | Aug 2016 → Apr 2017 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-11-08 | Daiichi Sankyo | Daiichi Sankyo Announces Positive Results from ESAX-DN Phase 3 Study in Japan of Esaxerenone in Patients with Diabetic Nephropathy daiichisankyo.com ↗ |
| 2018-02-27 | Daiichi Sankyo | Daiichi Sankyo Announces NDA submission in Japan of Esaxerenone for Treatment of Hypertension daiichisankyo.com ↗ |
| 2017-09-25 | Daiichi Sankyo | Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Study in Japan of Esaxerenone for Treatment of Essential Hypertension daiichisankyo.com ↗ |
| 2017-09-25 | Daiichi Sankyo | Daiichi Sankyo Initiates Pivotal Phase 3 study in Japan of Esaxerenone in Patients with Diabetic Nephropathy daiichisankyo.com ↗ |
| 2016-09-27 | Daiichi Sankyo | Daiichi Sankyo Initiates Phase 3 study of CS-3150, a Novel Mineralocorticoid Receptor Antagonist for Treatment of Essential Hypertension daiichisankyo.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS-3150 | “Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).” PMID 31786983 ↗ Dec 2019 |
| Known as | esaxerenone | “This post hoc exploratory substudy of a long-term phase 3 study evaluated the effect of esaxerenone monotherapy (2.5 or 5 mg/day) in treatment-naïve patients who continued the...” PMID 35976603 ↗ Aug 20221“Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).” PMID 31786983 ↗ Dec 2019 |
| Known as | XL-550 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545393 ↗ |
| Action | Inhibit | “esaxerenone, a new selective nonsteroidal MR blocker” PMID 31786983 ↗ Dec 20191“Mineralocorticoid receptor antagonist” CHEMBL3545393 ↗ |
| Route | Oral | “administered orally” NCT02345044 ↗ |
| Target | NR3C2 | “Mineralocorticoid receptor antagonist” CHEMBL3545393 ↗ |